A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Clinical trial NCT05121948 · TERMINATED

Trial details

NCT number: NCT05121948
Sponsor: HiberCell, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Squamous Cell Carcinoma of Head and Neck Colo-rectal Cancer Non Small Cell Lung Cancer Transitional Cell Carcinoma of the Bladder Other Solid Tumors Clear Cell Renal Cell Carcinoma

Start date: 2022-02-23
Primary completion: 2024-02-09
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.